US FDA closes inspection of Biocon’s insulin facility

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Master1305)
(Image: Getty/Master1305)

Related tags Biocon Malaysia Insulin

The company announces that the problems raised by the FDA in February have been cleared.

Towards the end of February, Biocon released a statement via the National Stock Exchange of India that an inspection by the US Food and Drug Administration (FDA) had resulted in three observations​.

The Johor, Malaysia, site had been visited as part of a pre-approval inspection for its insulin glargine product, which the company plans to commercialize alongside Mylan​.

However, the observations could have proved a stumbling block to entering the US market, though at the time Biocon had stated that it did not expect the inspection outcome to impact its plans for launching in the US.

Now, Biocon has provided an update that its insulin manufacturing facility had been closed with a ‘VAI’ (voluntary action indicated). As a result, the inspection of facility is closed by the FDA.

Mylan is currently proceeding with its application process to FDA for Semglee (insulin glargine)’s approval, with the potential product currently on review.

Semglee is currently approved in various countries globally, including in Europe as a biosimilar to existing insulin glargine products.

As of last month​, the FDA will now review insulin products as biologics and therefore as biosimilars – though Mylan and Biocon are proceeding with a new drug application (NDA).

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more